Cosette M. Wheeler

Overview

Best Publications

• Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

  Suzanne M. Garland;Suzanne M. Garland;Mauricio Hernandez-Avila;Cosette M. Wheeler;Gonzalo Perez

  2508
  Citations

• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

  Diane M. Harper;Eduardo L. Franco;Cosette Wheeler;Daron Gale Ferris

  2367
  Citations

• Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

  J. Paavonen;P. Naud;J. Salmeron;C. M. Wheeler

  2329
  Citations

• Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

  Diane M Harper;Eduardo L Franco;Cosette M Wheeler;Anna-Barbara Moscicki

  2212
  Citations

• A controlled trial of a human papillomavirus type 16 vaccine.

  Laura A. Koutsky;Kevin A. Ault;Cosette M. Wheeler;Darron R. Brown

  2044
  Citations

• Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

  Luisa L. Villa;Ronaldo L.R. Costa;Carlos A. Petta;Rosires P. Andrade

  1977
  Citations

• Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

  Jorma Paavonen;David Jenkins;F. Xavier Bosch;Paulo Naud

  1955
  Citations

• Improved Amplification of Genital Human Papillomaviruses

  P. E. Gravitt;C. L. Peyton;T. Q. Alessi;C. M. Wheeler

  1428
  Citations

• Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes : updated systematic review and meta-analysis

  Mélanie Drolet;Élodie Bénard;Norma Pérez;Marc Brisson;Marc Brisson

  1065
  Citations

• Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

  Matti Lehtinen;Jorma Paavonen;Cosette M. Wheeler;Unnop Jaisamrarn

  935
  Citations

• Genotyping of 27 Human Papillomavirus Types by Using L1 Consensus PCR Products by a Single-Hybridization, Reverse Line Blot Detection Method

  P. E. Gravitt;C. L. Peyton;R. J. Apple;C. M. Wheeler

  815
  Citations

• Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

  Elmar A Joura;Sepp Leodolter;Mauricio Hernandez-Avila;Cosette M Wheeler

  800
  Citations

• American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors

  Debbie Saslow;Philip E. Castle;J. Thomas Cox;Diane D. Davey

  771
  Citations

• Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.

  Constance Mao;Laura A. Koutsky;Kevin A. Ault;Cosette M. Wheeler

  697
  Citations

• Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

  Cosette M. Wheeler;Xavier Castellsagué;Suzanne M. Garland;Anne Szarewski

  678
  Citations

• Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

  Luisa L. Villa;Kevin A. Ault;Anna R. Giuliano;Ronaldo L.R. Costa

  666
  Citations

• The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16–26 Years

  Darron R. Brown;Susanne K. Kjaer;Kristján Sigurdsson;Ole-Erik Iversen

  589
  Citations

• Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective.

  T Yamada;M M Manos;J Peto;C E Greer

  573
  Citations

• Identification and Assessment Of Known And Novel Human Papillomaviruses by Polymerase Chain Reaction Amplification, Restriction Fragment Length Polymorphisms, Nucleotide Sequence, and Phylogenetic Algorithms

  Hans-Ulrich Bernard;Shih-Yen Chan;M. Michele Manos;Chi-Keong Ong

  541
  Citations

• Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

  Nubia Munoz;Susanne K. Kjaer;Kristján Sigurdsson;Ole Erik Iversen

  518
  Citations